Is Seer, Inc. (SEER) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 25.9% / 30% | 236.1% / 30% | 6.2% / 30% | 119.5% / 5% | ✗ NOT HALAL |
| DJIM | 25.9% / 33% | 236.1% / 33% | 6.2% / 33% | 119.5% / 5% | ✗ NOT HALAL |
| MSCI | 7.1% / 33% | 64.5% / 33% | 1.7% / 33% | 119.5% / 5% | ✗ NOT HALAL |
| S&P | 25.9% / 33% | 236.1% / 33% | 6.2% / 33% | 119.5% / 5% | ✗ NOT HALAL |
| FTSE | 7.1% / 33% | 64.5% / 33% | 1.7% / 50% | 119.5% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 51.1% | |
| Operating Margin | -413.8% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -25.1% | |
| Return on Assets (ROA) | -14.7% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$44M |
| Free Cash Flow | -$46M |
| Total Debt | $24M |
| Debt-to-Equity | 9.1 |
| Current Ratio | 12.8 |
| Total Assets | $296M |
Price & Trading
| Last Close | $1.69 |
| 50-Day MA | $1.85 |
| 200-Day MA | $2.01 |
| Avg Volume | 277K |
| Beta | 1.7 |
|
52-Week Range
$1.62
| |
About Seer, Inc. (SEER)
Seer, Inc., a life sciences company, develops and commercializes products to decode the biology of the proteome to improve human health in the United States, China, Australia, Europe, Israel, Japan, and South Africa. The company offers Proteograph Product Suite, an integrated solution, which includes proprietary engineered nanoparticles, consumables, automation instrumentation, and data analysis software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only. The company also offers Proteograph ONE, a third-generation assay; Proteograph DIRECT, which provides an automated approach for direct digestion of samples for bottom-up LC-MS proteomic analysis; and Proteograph Analysis Suite, a data analytics software suite designed to support quality control, data management, and interpretation of Proteograph output which is currently offered as a cloud-based solution. It markets and sells its products for research use only, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Seer, Inc. (SEER) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Seer, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Seer, Inc.'s debt ratio?
Seer, Inc.'s debt ratio is 25.9% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 7.1%.
What are Seer, Inc.'s key financial metrics?
Seer, Inc. has a market capitalization of $94M, and revenue of $16M. Return on equity stands at -25.1%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.